A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 401
- 试验地点
- 1
- 主要终点
- Incidence of DLTs
研究概览
简要总结
This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
详细描述
The study will start with a dose escalation of oral ABSK141 in patients with advanced solid tumors harboring KRAS G12D mutation to evaluate safety, tolerability, and PK. The expansion part will investigate oral ABSK141 at the recommended doses for expansion (RDEs) to evaluate safety and efficacy among selected tumor types harboring KRAS G12D mutation and optimize the dosage.
The phase II study will further investigate oral ABSK141 at the recommended phase 2 doses (RP2Ds) to evaluate safety and efficacy among selected tumor types harboring KRAS G12D mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients should understand, sign, and date the written informed consent form prior to screening
- •Male or female age 18 years or older
- •Patients with histologically confirmed locally-advanced or metastatic solid tumors .
- •For backfill cohorts in the escalation part:
- •Patients must have the following solid tumor harboring KRAS G12D mutation:
- •Colorectal cancer (CRC);
- •Non-small cell lung cancer (NSCLC);
- •Pancreatic ductal adenocarcinoma (PDAC);
- •Patients must have at least one measurable target lesion according to RECIST 1.1
- •For expansion Part:
- •Patients must have the following solid tumor harboring KRAS G12D mutation:
- •Colorectal cancer (CRC);
- •Non-small cell lung cancer (NSCLC);
- •Pancreatic ductal adenocarcinoma (PDAC);
- •Other solid tumors;
- •Patients must have at least one measurable target lesion according to RECIST 1.1
- •For phase II:
- •Patients with locally advanced or metastatic solid tumors confirmed by histological examination, whose disease has progressed after standard treatment or who are intolerant to standard treatment, or for whom there is currently no standard treatment.
- •Patients must have the following solid tumor harboring KRAS G12D mutation:
- •Colorectal cancer (CRC);
- •Non-small cell lung cancer (NSCLC);
- •Pancreatic ductal adenocarcinoma (PDAC);
- •Other solid tumors;
- •Patients must have at least one measurable target lesion according to RECIST 1.1
- •ECOG performance status 0 or 1
- •Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug
- •For patients participating exploration of food effect:
- •(1) be able to eat a standardized high-fat, high caloric meal within 30 minutes (2) be able to fast for 10 hours
排除标准
- •Known allergy or hypersensitivity to any component of the investigational product
- •(For backfill cohorts and expansion part) Patients who were previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy
- •Has a known additional malignancy that is progressing or has required active treatment
- •Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. If any of these conditions exist, the site should discuss with the sponsor to determine patient eligibility
- •Previous anti-tumor therapy, including chemotherapy, endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life (whichever is shorter), radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment
- •Major surgery within 4 weeks of the first dose of study drug. Note that all surgical wounds must be healed and free of infection or dehiscence
- •Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity (CTCAE v5.0)
- •Patients should not use proton pump inhibitors for at least 7 days prior to the first dose of ABSK141 and during treatment with ABSK
- •P-gp inhibitor and strong CYP3A inhibitors to 7 days or 5 half-lives whichever is longer and for CYP3A inducers to 2 weeks or 5 half-lives
- •Active central nervous system (CNS) metastases
- •History of interstitial lung disease requiring systemic steroid treatment.
- •Impaired cardiac function or clinically significant cardiac disease
- •NSCLC cohorts: Patient previously identified as having a driver mutation (according to local standard of care or guidelines) and have not received any targeted therapy, for example: EGFR mutation, ALK rearrangement, KRAS G12C mutation, NTRK1/2/3 gene fusion, RET fusion, MET exon14 skipping mutation, BRAF V600E mutation, ROS1 rearrangement, etc
- •Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1/2 antibody
- •Exclusion of hepatitis infection
- •Patients with refractory/uncontrolled ascites or pleural effusion
- •Pregnant or nursing (lactating) women
- •refuse to use highly effective methods of birth control during the study and for up to 6 months after the last dose of study drug.
- •Sexually active males who refuse to use a condom during intercourse while taking drug and for 5 consecutive compound half-lives plus 60 days after stopping study drug.
- •Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines
- •Planned major surgery during study treatment
- •Any other clinically significant comorbidities
研究组 & 干预措施
Escalation part-400mg
ABSK141 (investigational drug) tablet, 400 mg administered orally once daily (QD), continuously until disease progression.
干预措施: ABSK141-400mg (Drug)
expansion part
ABSK141 (investigational drug) tablet,Recommended Dose for Expansion (RDE) administered orally once daily (QD), continuously until disease progression.
干预措施: ABSK141-Recommended Dose for Expansion (RDE) (Drug)
Escalation part-800mg
ABSK141 (investigational drug) tablet, 800 mg administered orally once daily (QD), continuously until disease progression.
干预措施: ABSK141-800mg (Drug)
Escalation part-1200mg
ABSK141 (investigational drug) tablet, 1200 mg administered orally once daily (QD), continuously until disease progression.
干预措施: ABSK141-1200mg (Drug)
Backfill cohorts
ABSK141 (investigational drug) tablet, The decision-making on doses for backfill cohorts will be based on the discussion and alignment between the Sponsor and Investigator.
干预措施: ABSK141-Recommended Dose for Expansion (RDE) (Drug)
Phase II
ABSK141 (investigational drug) tablet, administered at the Recommended Phase 2 Dose (RP2D) continuously until disease progression.
干预措施: ABSK141-Recommended Phase 2 dose (RP2D) (Drug)
结局指标
主要结局
Incidence of DLTs
时间窗: from Run-in to Day28
dose-limiting toxicities
Incidence and severity of AEs
时间窗: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.
Adverse events
Incidence and severity of SAEs
时间窗: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.
serious adverse events
次要结局
- CL/F(From pre-dose to up to 72 hours post-dose)
- tmax(From pre-dose to up to 72 hours post-dose)
- ORR(From the first dose date to the date of first confirmed response (CR/PR), assessed up to 24 months.)
- AUC(From pre-dose to up to 72 hours post-dose)
- Cmax(From pre-dose to up to 72 hours post-dose)
- t1/2(From pre-dose to up to 72 hours post-dose)
- DOR(From date of first confirmed response (CR/PR) to date of first documented progression (PD) or death from any cause, whichever comes first, assessed up to 24 months.)
- PFS(From the first dose date to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first, assessed up to 24 months.)
- DCR(From the first dose date to the date of first documented disease status assessment (CR/PR/SD/PD), assessed up to 24 months.)
- OS(From the first dose date to the date of death from any cause, assessed up to24 months)